MICHAEL BEST STRATEGIES LLC

Lobbying for SAREPTA THERAPEUTICS · Medical research and drug development company

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · Massachusetts · House · Senate · $110,000.00 income · posted Jan 20, 2026

Lobbying activity 2

Health Issues

Scientific innovation in healthcare including gene therapy, rare diseases including Duchenne muscular dystrophy

Medical/Disease Research/Clinical Labs

Scientific innovation in healthcare including gene therapy, rare diseases including Duchenne muscular dystrophy

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.